Navigation Links
RenAvast for Cats and Dogs Will Now Be Distributed In Sweden, Denmark, Norway and Finland
Date:8/26/2014

Reno, NV (PRWEB) August 26, 2014

Bio Health Solutions, the developers and manufacturers of RenAvast, a nutritional supplement to support natural kidney function in cats and dogs, has entered into a 3 year distribution agreement with VetNutra to distribute RenAvast to veterinarians in Sweden, Denmark, Norway and Finland.

RenAvast is a high quality, effective product used to support natural kidney function in cats and dogs. RenAvast is 100% safe with no reported side effects. RenAvast is a combination of naturally occurring amino acids and peptides. Cats and dogs have seen improvements within weeks of starting RenAvast. Reported improvements include but are not limited to coat improvement, increased appetite, decreased vomiting, weight gain and a general all over sense of feeling better.

Prior to entering this distribution agreement, VetNutra distributed over 100 bottles of feline Renavast to several veterinary clinics in Sweden. The veterinarians were extremely satisfied with the positive results they saw with cats which prompted VetNutra to move forward with a distribution agreement.
Bio Health Solutions is committed to developing safe, effective, high quality products to improve and extend the lives of humans and their companion animals. All products are manufactured at a FDA licensed manufacturing facility. The manuscript for the study of RenAvast is pending peer review publication. For details about the specific ingredients contact Bio Health Solutions.

Visit http://www.renavast.com and http://www.biohealthsolutions.com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12120073.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Moffitt Cancer Center researchers analyze how Spanish smoking relapse booklets are distributed
2. Pwnie Express Releases Citadel PX for Distributed Penetration Testing
3. Almost Nuts! Now Being Distributed by L&L Foods
4. The Lancet: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials
5. The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine
6. USD $1.15 Billion Commitment over Three Years to Help Save the Lives of Children and Women Secured through World Bank, UNICEF, USAID and Norway
7. OxBlue Continues International Expansion in Multi-Use Green Project in Norway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: